T786C eNOS polymorphism as risk factor for recurrent myocardial infarction in young and middleaged patients
https://doi.org/10.33667/2078-5631-2020-28-17-21
Abstract
Objective. To determine the possible role of the endothelial nitric oxide synthase (eNOS) polymorphism T786C (rs 2070744) in developing of recurrent myocardial infarction (MI) in young and middle-aged patients. Materials and methods. 114 patients with acute MI treated with percutaneous coronary intervention and thrombolysis that were admitted to Clinical cardiologic dispensary (Perm city, Russia) were enrolled into a study. Among them there were 28 patients with recurrent MI. The eNOS T786C polymorphism were determined by real-time PCR. Results. In T786C polymorphism of eNOS, compared with the T/T genotype, it was determined that those with T/C has 2,27 fold (95 % CI: 1.01–5.49), and those with the CC genotype has 2.22 times (95 % CI: 1.30–8.53) (p = 0.034) greater risk of developing recurrent MI. Patients with severe coronary arteries atherosclerosis more frequently had eNOS T786C polymorphism of T/C genotype (OR = 4,67; 95 % CI: 1,38–15,37; p = 0,031). Conclusion. The eNOS T786C variants could be evaluated as recurrent MI risk factor in young and middle-aged patients.
About the Authors
E. A. Shishkina
Perm State Medical University n. a. E. A. Wagner
Russian Federation
Perm
Russian Federation
Perm
O. V. Khlynova
Perm State Medical University n. a. E. A. Wagner
Russian Federation
Perm
Russian Federation
Perm
A. V. Tuev
Perm State Medical University n. a. E. A. Wagner
Russian Federation
Perm
Russian Federation
Perm
A. V. Krivtsov
Federal Research Center for Medical and Preventive Technologies for Managing Public Health Risks
Russian Federation
Perm
Russian Federation
Perm
References
1. Samorodskaya I. V., Boytsov S. A. Subsequent myocardial infarction: risk assessment and prevention. Russian Journal of Cardiology. 2017; (6): 139–145 (in Russ.) https://doi.org/10.15829/1560-4071-2017-6-39-145
2. Kireeva V. V., Koch N. V., Lifshits G. I., Apartsin K. A. Endothelial dysfunction ascornerstone of cardiovascular events: molecular and pharmaceutic aspects. Russ J Cardiol. 2014; 19 (10): 64–8. (In Russ) https://doi.org/10.15829/1560-4071-2014-10-64-68
3. Gimbrone M. A., García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circulation Research. 2016; 118 (4): 620–636. https://doi.org/10.1161/CIRCRESAHA.115.306301
4. Luizon M., Pereira D., Tanus–Santos J. Pharmacogenetic relevance of endothelial nitric oxide synthase polymorphisms and gene interactions. Pharmacogenomics. 2018; 19 (18): 14231435. https://doi.org/10.2217/pgs-2018-0098
5. Thygesen K., Alpert J., Jaffe A., et al. Fourth Universal Definition of Myocardial Infarction (2018). Journal of the American College of Cardiology. 2018; 72 (18): 22312264. https://doi.org/10.1161/CIR.0000000000000617
6. Gensini G. A more meaningful scoring system for determining the severity of coronary artery disease. Am J Cardiol. 1983; 51: 606. https://doi.org/10.1016/s0002-9149(83)80105-2
7. Balci S., Yildiz P., Sucu N., Yilmaz D.C, Tamer L. T786C and G894T eNOS Polymorphisms as a Risk Assessment of Coronary Artery Disease. J Cardiol Curr Res. 2017; 8 (4): https://doi.org/10.15406/jccr.2017.08.00290
8. Narne P., Ponnaluri K. C., Singh S., Siraj M., Ishaq M. Association of the genetic variants of endothelial nitric oxide synthase gene with angiographically defined coronary artery disease and myocardial infarction in South Indian patients with type 2 diabetes mellitus. Journal of Diabetes and its Complications. 2013; 27 (3): 255–261. https://doi.org/10.1016/j.jdiacomp.2012.10.009
9. Zeng W. P., Zhang R., Li R., Luo J. F., Hu X. F. Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery DiseaseTreated with Drug Eluting Stent. PloS one. 2017; 12 (1): e0170964. https://doi.org/10.1371/journal.pone.0170964
10. Muslimova E. F., Rebrova T. Yu., Afanasiev S. A., Sergienko T. N., Repin A. N. Genotype –786CC of the endothelial nitric oxide synthase gene NOS 3 as a factor of adverse coronary heart disease course and increased on-treatment platelet aggregation. Russ J Cardiol. 2017; 10 (150): 29–32. (In Russ.) http://dx.doi.org/10.15829/1560-4071-2017-10-29-32
11. Petyunina O., Kopytsy M. Babichev D. Berezin A. Short-term clinical outcomes in patients with acute myocardial infarction after successful percutaneous coronary revascularization: the role of promoter polymorphism of the endothelial nitric oxide synthase gene. Biomedical Research and Therapy. 2019; 6 (5): 3166–3179. https://doi.org/10.15419/bmrat.v6i5.543
12. Kiani A., Nazarabad V., Ahmadi K., Anbari K., Ahmadi B. Polymorphisms of endothelial nitric oxide synthase and hypoxia-inducible factor 1 alpha genes play a role in susceptibility to coronary artery disease. Biomedical Research and Therapy. 2018; 5 (9): 2688–2696. https://doi.org/10.15419/bmrat.v5i9.480
13. Kandhai-Ragunath J.J., Doggen C. J., Jørstad H. T., Doelman C, de Wagenaar B, IJzerman MJ, Peters RJ, von Birgelen C. Endothelial Dysfunction After ST-segment Elevation Myocardial Infarction and Long-term Outcome: A Study With Reactive Hyperemia Peripheral Artery Tonometry. Rev Esp Cardiol (Engl Ed). 2016; 69 (7): 664–671. https://doi.org/10.1016/j.rec.2015.12.020
Review
For citations:
Shishkina E.A., Khlynova O.V., Tuev A.V., Krivtsov A.V. T786C eNOS polymorphism as risk factor for recurrent myocardial infarction in young and middleaged patients. Medical alphabet. 2020;(28):17-21. (In Russ.) https://doi.org/10.33667/2078-5631-2020-28-17-21
Views:
453
Email this article 